Tilsotolimod - Idera Pharmaceuticals

Drug Profile

Tilsotolimod - Idera Pharmaceuticals

Alternative Names: IMO-2125

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idera Pharmaceuticals
  • Class Antineoplastics; Antivirals; Oligodeoxyribonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase I Solid tumours
  • Preclinical Colorectal cancer; Lymphoma; Pancreatic cancer
  • Discontinued Hepatitis C

Most Recent Events

  • 16 Apr 2018 Idera Pharmaceuticals enters into a clinical development support agreement with Pillar Partners Foundation for Non-small cell lung cancer, Head and neck cancer, Malignant melanoma and Urogenital cancer
  • 16 Apr 2018 Idera Pharmaceuticals, Pillar Partners Foundation and American University of Beirut Medical Center plan a phase II trial for Non-small cell lung cancer (Combination therapy) in Lebanon (Intratumoral)
  • 16 Apr 2018 Idera Pharmaceuticals, Pillar Partners Foundation and Institut Gustave Roussy plan a phase I/II trial for Non-small cell lung cancer, Head and neck cancer, Malignant melanoma and Urogenital cancer (Combination therapy) in France (Intratumoral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top